使用支气管舒张后或前参考值解读肺量计的后果
研究基于SCAPIS队列比较支气管舒张前后参考值对肺量计异常检出率的影响。结果显示,使用舒张后参考值使气流阻塞患病率翻倍(9.9% vs 4.8%),额外识别人群呼吸症状和肺气肿更多。建议解读舒张后肺量计时采用舒张后参考值以识别轻度疾病。
要点
- 支气管舒张后参考值较舒张前参考值预测中位数更高、LLN更低,影响FEV1/FVC判读。
- 使用舒张后参考值使气流阻塞患病率从4.8%升至9.9%,额外识别5.1%异常者。
- 额外识别者呼吸症状、肺气肿(13.5% vs 4.1%)和COPD诊断(2.8% vs 0.5%)更多。
核心结论
- 支气管舒张前后肺量计参考值在FEV1/FVC比值上存在差异,使用舒张后参考值使气流阻塞患病率翻倍,并与更高呼吸负担相关。
- 解读支气管舒张后肺量计时使用舒张后参考值可能有助于识别轻度疾病个体,具有临床相关性。
研究设计与样本
- 基于SCAPIS(瑞典心肺生物影像研究)的参考值研究,舒张后参考值基于10,156名从不吸烟健康参与者,舒张前参考值基于1,498名。
- 在SCAPIS一般人群(28,851人)中研究异常肺量计(分别用舒张前或舒张后参考值定义)与呼吸负担的关联。
主要发现
- 支气管舒张导致FEV1/FVC比值的预测中位数更高、正常下限(LLN)更低。
- 一般人群中,舒张后FEV1/FVC低于舒张前LLN的患病率为4.8%,低于舒张后LLN的患病率为9.9%。
- 额外5.1%被识别为舒张后FEV1/FVC异常,该组呼吸症状更多、肺气肿比例更高(13.5% vs. 4.1%;P < 0.001)、医生诊断COPD比例更高(2.8% vs. 0.5%,P < 0.001)。
临床怎么用
- 解读支气管舒张后肺量计时,应考虑使用支气管舒张后参考值而非舒张前参考值,以避免低估气流阻塞。
- 使用舒张后参考值可识别更多有呼吸症状和肺气肿的轻度异常个体,可能有助于早期干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Postbronchodilator spirometry is used for the diagnosis of chronic obstructive pulmonary disease. However, prebronchodilator reference values are used for spirometry interpretation. Objectives: To compare the resulting prevalence rates of abnormal spirometry and study the consequences of using pre- or postbronchodilator reference values generated within SCAPIS (Swedish CArdioPulmonary bioImage Study) when interpreting postbronchodilator spirometry in a general population. Methods: SCAPIS reference values for postbronchodilator and prebronchodilator spirometry were based on 10,156 and 1,498 never-smoking, healthy participants, respectively. We studied the associations of abnormal spirometry, defined by using pre- or postbronchodilator reference values, with respiratory burden in the SCAPIS general population (28,851 individuals). Measurements and Main Results: Bronchodilation resulted in higher predicted medians and lower limits of normal (LLNs) for FEV1/FVC ratios. The prevalence of postbronchodilator FEV1/FVC ratio lower than the prebronchodilator LLN was 4.8%, and that of postbronchodilator FEV1/FVC lower than the postbronchodilator LLN was 9.9%, for the general population. An additional 5.1% were identified as having an abnormal postbronchodilator FEV1/FVC ratio, and this group had more respiratory symptoms, emphysema (13.5% vs. 4.1%; P < 0.001), and self-reported physician-diagnosed chronic obstructive pulmonary disease (2.8% vs. 0.5%, P < 0.001) than subjects with a postbronchodilator FEV1/FVC ratio greater than the LLN for both pre- and postbronchodilation. Conclusions: Pre- and postbronchodilator spirometry reference values differ with regard to FEV1/FVC ratio. Use of postbronchodilator reference values doubled the population prevalence of airflow obstruction; this was related to a higher respiratory burden. Using postbronchodilator reference values when interpreting postbronchodilator spirometry might enable the identification of individuals with mild disease and be clinically relevant.
引用
- Malinovschi A, Zhou X, Andersson A, et al. Consequences of Using Post- or Prebronchodilator Reference Values in Interpreting Spirometry. Am J Respir Crit Care Med. 2023. PMID: 37339507. doi:10.1164/rccm.202212-2341OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。